A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Results from published open-label clinical trials of Janus kinase inhibitors in patients with alopecia areata suggest that they can reverse hair loss. Treatment with ritlecitinib and brepocitinib for 24 weeks was well tolerated and resulted in clinically significant hair regrowth in patients with alopecia areata with ≥50% scalp hair loss.